Phenothiazine-based theranostic compounds for in vivo near-infared fluorescence imaging of β-amyloid plaques and inhibition of Aβ aggregation
Source abstract
Abstract
Abstract A global burden of Alzheimer's disease (AD) has been growing over last decades. Evidence indicates that β-amyloid (Aβ) production and senile plaque deposition in the brain is causative in the onset of AD pathogenesis. It appears much earlier than cognitive decline and plays a key role in initiating and developing AD neuropathology. As such, there is an intense passion with discovering theranostic agents which make a significant impact in diagnostic and therapy. Herein, we report an investigation of novel phenothiazine-based compounds as promising potential theranostic agents for AD. Remarkably, they have exhibited a high binding affinity toward Aβ aggregates, a good biostability and a strong increase in their fluorescence intensity with blue shift when interacting with Aβ aggregates. Furthermore, they have been simultaneously applied to perform NIR in vivo imaging of β-amyloid plaques in double transgenic AD mouse model, to prevent self-aggregation of Aβ monomer from forming toxic oligmers and to reduce Aβ-induced toxicity of human neuroblastoma cells (SH-SY5Y).
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Alzheimer's disease research and treatments · Cholinesterase and Neurodegenerative Diseases · Tryptophan and brain disorders
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (35)
Show source-provided references
1. Alzheimer disease therapy--moving from amyloid-β to tau10.1038/nrneurol.2013.223 ↗
2. Resolving controversies on the path to Alzheimer's therapeutics10.1038/nm.2460 ↗
3. NIA commentary: translational issues in Alzheimer's disease drug development10.1038/npp.2011.116 ↗
4. Perspectives on inhibiting β-amyloid aggregation through structure-based drug design10.1002/cmdc.201500215 ↗
5. Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease10.2174/157488911796958002 ↗
6. Mitochondrial Abeta: a potential cause of metabolic dysfunction in Alzheimer's disease10.1080/15216540601047767 ↗
7. Amyloid beta -protein (Abeta) assembly: abeta 40 and Abeta 42 oligomerize through distinct pathways10.1073/pnas.222681699 ↗
8. Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease10.1038/aps.2011.14 ↗
9. Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease10.1093/brain/awt362 ↗
10. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration10.1073/pnas.1017033108 ↗
11. Synaptic memory mechanisms: Alzheimer's disease amyloid beta-peptide-induced dysfunction10.1042/BST0351219 ↗
12. Soluble amyloid-beta peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo10.1093/brain/awn174 ↗
13. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease10.1016/j.molmed.2007.12.002 ↗
14. Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer's disease10.2174/156720509790147070 ↗
15. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options10.2174/157015909787602823 ↗
16. Dysregulation of calcium in Alzheimer's disease10.55782/ane-2003-1465 ↗
17. Bolognesi · 2013
18. Alzheimer's disease: the challenge of the second century10.1126/scitranslmed.3002369 ↗
19. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics10.1126/science.1072994 ↗
20. Amyloid beta: structure, biology and structure-based therapeutic development10.1038/aps.2017.28 ↗
21. Toward a rational design to regulate β-amyloid fibrillation for Alzheimer's disease treatment10.1021/acschemneuro.7b00477 ↗
22. Optical and opto-acoustic interventional imaging10.1007/s10439-011-0501-4 ↗
23. Fluorescence molecular tomography: principles and potential for pharmaceutical research10.3390/pharmaceutics3020229 ↗
24. In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe10.1038/nbt1085 ↗
25. In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers10.1002/anie.200500845 ↗
26. Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid-beta deposits10.1021/ja9047043 ↗
27. BODIPY-based molecular probe for imaging of cerebral β-amyloid plaques10.1021/cn3000058 ↗
28. Development of phenothiazine-based theranostic compounds that act both as inhibitors of β-amyloid aggregation and as imaging probes for amyloid plaques in Alzheimer's disease10.1021/acschemneuro.6b00380 ↗
29. Validation of the general purpose tripos 5.2 force field10.1002/jcc.540100804 ↗
30. Polarisation nucleaire induite chimiquement: etude comparative de la decomposition thermique et photochimique de peroxydes d'acyle benzoyle10.1016/0040-4020(80)80168-2 ↗
31. Charge distribution from molecular topology and orbital electronegativity
32. Unraveling the photoluminescence response of light-switching ruthenium(II) complexes bound to amyloid-β10.1021/ja404850u ↗
33. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo10.1074/jbc.M404751200 ↗
34. Binding of Congo red to amyloid protofibrils of the Alzheimer Aβ(9-40) peptide probed by molecular dynamics simulations10.1016/j.bpj.2012.07.008 ↗
35. Dual binding modes of Congo red to amyloid protofibril surface observed in molecular dynamics simulations10.1021/ja0662772 ↗